RxDoctor Payments Data

Lawrence Pardee, MD

Neurology · Canandaigua, NYNPI 1417963166

Payments from drug & device makers

$159,258in general payments, 2019–2025

Across 1,306 payments — averaging $121.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$84K
  • Teva Pharmaceuticals USA, Inc.$22K
  • Biohaven Pharmaceuticals, Inc.$16K
  • Sanofi$11K
  • Biohaven Pharmaceutical Holding Company Ltd.$10K
  • Lundbeck LLC$3K
  • plus $13K from 45 others

What the payments were for

  • Consulting fees$3,0502%
  • Speaking & faculty fees$133,34284%
  • Travel & lodging$1,7111%
  • Food & beverage$20,66713%
  • Education$4880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$159,258 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$123,579
Medicare patients
184
Services billed
12,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate19$192,045
CopaxoneGlatiramer Acetate19$128,838
IngrezzaValbenazine Tosylate12$102,515
FingolimodFingolimod Hcl12$70,532
Ajovy AutoinjectorFremanezumab-Vfrm53$56,770
NourianzIstradefylline12$41,224
Dalfampridine ErDalfampridine15$28,131
Nurtec OdtRimegepant Sulfate27$27,285
QuliptaAtogepant22$22,813
XcopriCenobamate13$21,858
Aimovig AutoinjectorErenumab-Aooe24$18,288
Topiramate ErTopiramate26$15,729
Rasagiline Mesylate79$15,119
UbrelvyUbrogepant11$10,239
Emgality PenGalcanezumab-Gnlm13$9,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$409$192,04519 claims
Teva Pharmaceuticals USA, Inc.Copaxone$21,930$128,83819 claims
Neurocrine Biosciences, Inc.Ingrezza$2,709$102,51512 claims
Kyowa Kirin, Inc.Nourianz$136$41,22412 claims
AbbVieQulipta, Ubrelvy$84,074$33,05333 claims
PfizerNurtec Odt$2,813$27,28527 claims
SK Life Science, Inc.Xcopri$189$21,85813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →